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Stlmmary 
In the preceding article, we analyzed the immunohistochemical  rejection mechanism of major 
histocompatibility complex (MHC) class I  (H-2K)-disparate  murine  skin grafts,  and showed 
that only CD8 + cells infiltrated at the site of the epithelial  tissue of MHC dass I-disparate graft. 
We also showed that perfect survival of MHC dass I-disparate grafts were attained in thymectomized 
recipients treated with anti-Lyt-2 monoclonal antibody. In this report,  we showed that  these 
long-surviving allo-class I grafts were rejected in the absence of CD8 + cells by stimulation with 
allo-MHC  class  I  +  II-disparate  graft  as  the  second  stimulation.  Furthermore,  it  was 
immunohistochemically  revealed  that  under  that  condition,  a large  number  of CD4 +  cells 
infiltrated into the epithelial tissue of these long-surviving class I grafts, which were going to 
be rejected 2-5 d after the transplantation  of a second graft with MHC class I  +  II difference. 
This result directly shows that CD4 + cells are able to became effectors for the rejection of allo- 
MHC class  I  (H-2K)  skin graft. 
M 
ature peripheral  T  cells  are classified  into  CD4 +  or 
. CD8 + subsets according to the difference in cell sur- 
face marker  (1, 2). Many recent investigators have clarified 
the mode of action of these T  cell subsets in terms of reac- 
tivities to allogeneic MHC class I or II antigens. CD8 + cells 
react  predominantly  with  allo-MHC class  I  antigens,  and 
CD4 + cells react selectively with aUo-MHC class II antigens 
(3, 4). There are also many reports showing that CD4 + Th 
cells recognize allo-MHC class I antigen in association with 
self-Ia structure, and help the generation of CD8 + cytotoxic 
T  cells (Tc) in the in vitro system (5, 6). A similar mecha- 
nism is considered to be involved in the rejection of skin graft. 
In preceding articles (7-9), we immunohistochemically ana- 
lyzed the rejection mechanism of murine skin graft different 
solely in MHC class I (H-2K) antigen, and showed that only 
CD8 §  T  cells infiltrated  the epithelial  tissue of the graft. 
Furthermore,  it was shown that  CD4 + cells  were not in- 
volved in the rejection ofallo-MHC class I (H-2K)-disparate 
skin graft in thymectomized recipients treated with anti-Lyt-2 
mAb (10). On the contrary, there is a report suggesting that 
CD4 +  cells  may be able to mediate  the  rejection  of skin 
graft with MHC class I difference (11).  In this article,  we 
examine whether or not CD4 + T  cells are able to react in 
vivo with aUo-MHC class I antigen under the experimental 
condition in which CD8 + T  cells are totally depleted from 
the recipient. It is shown that CD4 + T  cells do mediate the 
rejection of aUo-MHC class  I-disparate  graft.  The mecha- 
nism  of such a phenomenon  is discussed. 
Materials and Methods 
Mice.  Female  C57BL/6 (B6) mice, either  thymectomized  or 
untreated,  were used as skin graft  recipients. Male B6.C-H-2 ~1 
(bml) mice, which carry mutant gene at the H-2K locus, and B6.C- 
1-1-2  ~2 (bin12) mice with mutation at I-A region,  were used to 
obtain Fx hybrids between B6 mice. These strains of mice were 
originally derived from The Jackson Laboratory (Bar Harbor, ME). 
When thymectomized recipients were used, the operation was done 
at 6-7 wk of age and received the graft 4-6 wk later. All mice 
used in the transplantation  experiments were female to avoid the 
involvement of H-Y antigen. 
Administration  of mAtx  Anti-Lyt-2  (2.43)  and/or anti-L3T4 
(GK1.5) mAb were administered intraperitoneally at a dose of 0.5 
mg on days -4, 0, 7, 14, and 21 (day 0=day of skin grafting). 
This  protocol  was  shown  to  be  suf~cient  to  deplete  Lyt-2 + 
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50 d (to). 
Skin Grafting.  Doubly transplanted recipients were used for the 
experiments.  In the first grafting,  couple of full-thickness  skin pieces 
were taken from the dorsal part of a donor and transplanted  to 
a pair of graft beds prepared at the dorsal part of each recipient 
on day 0, as previously described (7-10). Recipients were 8-12-wk- 
old when the first grafting was done. Second graft was implanted 
on day 28 to another dorsal part near the long-surviving first grafts. 
Biopsy, Histological, and lmmunohistochemical Studies.  The first 
implanted grafts were observed every day through transparent  plaster 
which was removed on day 7. One of the paired grafts on each 
recipient was biopsied on days 7, 9, 11, and 13. In thymectomized 
B6 recipients  treated with anti-Lyt-2  mAb (B6  x  bml)Fl  skin 
grafts survived. The second graft was implanted on these recipients 
on the 28th day after the first grafting. One of the long-surviving 
paired grafts was biopsied on days 35, 37, 39, and 41, and both 
the counterpart  of the long-surviving graft and the second graft 
were observed to record the survival. The biopsied grafts were used 
for histological and immunohistochemical studies as previously de- 
scribed (7-10), to examine subsets of T cells infiltrating at the site 
of graft.  Sampling of one of the paired grafts did not affect the 
survival  of the other graft  (7). 
Flow Cytometn'c Analyses.  The degree of depletion of CD8 + 
cells and the presence of L3T4* (CD4 *) cells in the spleen of var- 
ious recipients were examined by flow cytometry. After spleen cell 
suspension  was  treated  with  hemolytic  buffer,  l&  cells  were 
reacted  with  appropriately  diluted  FITC-conjugated  anti-Lyt-2 
(53-6.7) or anti-L3T4 (GK1.5) mAb. The stained cells were fixed 
with  1%  paraformaldehyde  and  their  fluorescence  intensities 
were analyzed by FACScan |  (Becton Dickinson & Co., Mountain 
View,  CA). 
Results and Discussion 
Survival of MHC Class I--disparate Grafts.  Survival of MHC 
class I-disparate  [(B6  x  bml)F1]  grafts was followed,  and 
the results obtained are summarized in Fig.  I. The grafts to 
thymectomized B6 recipients were rejected at 11.5  -.+  2.5 d 
(mean  _  SD of four mice), almost at the same time as those 
to untreated intact B6 recipients. The grafts to euthymic mice 
treated with anti-Lyt-2  mAb were also rejected at the same 
time  as those to untreated  control.  The spleen cells of the 
euthymic recipients treated with anti-Lyt-2 mAb were tested 
on day 18 to confirm the effect of anti-Lyt-2 mAb treatment. 
Flow cytometric patterns  of the spleen cells showed almost 
complete depletion (to a background level of<0.6-1.2%)  of 
CD8 + cells from the spleen of anti-Lyt-2 mAb-treated mice, 
whereas  10.6-14.1%  of CD8 +  cells  were detected  in  the 
spleen  of untreated  mice  in  several  experiments.  As  was 
reported by others (12, 13), long survival of MHC class I-dis- 
parate skin graft was observed only in the group of thymec- 
tomized recipients treated with anti-Lyt-2  mAb.  In our ex- 
periment, completely accepted graft survived throughout  the 
observation  period  of 70 d. 
These  results  suggest  that  newly  recruited  CD8 +  cells 
from thymus become effectors to allo-MHC class I grafts in 
anti-Lyt-2  mAb-treated  host  as previously described  (10). 
From  our immunohistochemical  studies  (10),  we conclude 
that  CD4 + cells are not involved in the rejection of MHC 
too 
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Figure 1.  Survival of MHC class I-disparate skin grafts. Survival of(B6 
x  bml)F1 grafts on (a) intact B6 recipients (n  =  10); (b) euthymic 
recipients treated with anti-Lyt-2 mAb (n  =  10); (c) thymectomized 
recipients (n = 4); and (d) thymectomized  recipients treated with anti-Lyt-2 
mAb (n = 4). The grafts of (a-c), were rejected almost at the same time. 
Long survival of MHC class I-disparate grafts was observed only in (d). 
(e) Survival of (bml  x  bm12)F1 grafts implanted at day 28 on thymec- 
tomized and Lyt-2 mAb-treated recipients which carried (B6 x  bml)Ft 
skin grafts (n = 7). (f) Survival of long-standing allo-class I different grafts 
after the second allo-class I + II-different grafting on day 28. The second 
grafts of the group (e) were rejected at 8.9 _+ 0.9 d after the second grafting, 
and four of seven of 0  c) were also rejected 2-5 d later after rejection of 
the second graft. 
class I-disparate  skin grafts in our experimental  system. On 
the contrary,  CD4 + cells have been shown by others to have 
CTL  activity against  allo-MHC  class I  antigen  in  in vitro 
culture  (14,  15) and to mediate  skin graft rejection  against 
different  amounts  of transgenic  H-2K b antigen  (16).  To ex- 
amine possible involvement  of CD4 + cells in the rejection 
of allo-MHC  class  I  grafts  on  the  recipients  depleted  of 
CD8 +  cells,  second  graft  was  implanted  to  the  thymec- 
tomized recipients  which had been treated with anti-Lyt-2 
mAb and which had carried long-surviving  class I-disparate 
grafts.  When allo-class I graft was used as the second graft, 
both the first and second grafts survived for more than 70 d 
after the first grafting  (n  =  4). When  aUo-dass II [(B6  x 
bm12]F 0  graft was implanted  as second graft,  long-surviv- 
ing class I first grafts were not affected but class II-disparate 
second grafts were rejected at 9.5  __  1.0 d  (mean  _+  SD of 
four mice tested) after the grafting.  We have confirmed that 
effector for the rejection of MHC dass II-disparate skin graft 
was CD4 + T  cells, so that treatment  of the thymectomized 
hosts with anti-L3T4 mAb allowed long survival of the graft 
(8).  When  class I  +  II-different  [Osml  x  bm12)F,]  grafts 
were used as the  second grafts,  they were rejected at  10.8 
_  3.0 d,  and four of seven long-surviving  class I-different 
grafts were rejected 2-5 d later after the second graft rejec- 
tion  (Fig.  1 J).  In another  experiment,  we confirmed  that 
MHC class I  +  II-different skin grafts were completely taken 
by the recipients  (n  =  5) thymectomized  and treated with 
both anti-L3T4 and anti-Lyt-2 mAbs. This fact indicates that 
graft  rejection  in  our experimental  system was effected by 
either  CD4 +,  CD8 + cells,  or both. 
There are reports showing that CD4 + cells reacting with 
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findings of T cell subsets in MHC 
class I-disparate [(B6  x  bml)F1] 
graft. (a and c) CD4 § cells and (b 
and  d)  CD8 §  cells  detected  by 
avidin-biotin-peroxidase  complex 
staining  method  (original  mag- 
niiication x 150). (a and b) the graft 
of a euthymic B6 recipient treated 
with anti-Lyt-2  mAb, whose coun- 
terpart was rejected 2 d after the bi- 
opsy. Many of CD8*  cells (arrow- 
head) are seen in the epidermis (E) 
and hair follicles (H).  No CD4+ 
cells are infiltrating the epithelial 
tissue of the graft. (c and d) The 
long-standing class I-disparate graft 
on thymectomized and anti-Lyt-2 
treated B6 recipient 7 d  after the 
class  I  +  lI-disparate  [Coral  x 
bm12)F1] skin graft. The counter- 
part of the biopsied graft was re- 
jected  2  d  after  sampling.  No 
CD8 + cells are detected in the ep- 
ithelial  tissue.  On  the  contrary, 
many CD4 +  cells  (arrow) are  de- 
tected in E  and  H  of the  graft, 
showing focal satellite cell necrosis 
(large arrow). 
dass I aUoantigens presented in the context  of MHC  class 
II  antigens  help  the  activation  of CD8 +  Tc  which  act  as 
effectors  for the rejection  of MHC  dass  I-disparate  grafts 
(17, 18). Thus far, there are no reports directly showing that 
CD4 + T  cells per se mediated MHC dass I graft rejection. 
In this report, we showed that CD4 + cells activated by the 
stimulation with allo-dass I  +  II antigen induced the rejec- 
tion of allo-MHC class I graft without the participation of 
CD8 §  cells.  Depletion  of CD8 +  cells  in  thymectomized 
mice  treated  with  anti-Lyt-2  mAb  was  confirmed  by 
FACScan  |  on day 50 after the first  grafting.  In a preceding 
artide  (10),  we  showed  that  CD8 +  cells  were  immuno- 
histochemically detected at the site of allo-MHC dass I-differ- 
ent graft on anti-Lyt-2-treated  hosts,  even if this subset of 
619  Kobayashi et al.  Brief Definitive Report spleen cells was undetectable by flow cytometric analyses and 
mixed lymphocyte reaction against bin1  stimulator.  Con- 
sidering  these  previous  results,  the  following  immuno- 
histochemical examinations were performed. 
Immunohistological  Surveys  of  MHC  Class  1-disparate 
Grafts.  Immunohistochemical examination of the MHC class 
I-disparate  skin grafts of both  intact and thymectomized 
recipients  showed  that  only CD8 +  but  no  CD4 +  were 
infiltrating at the site of the epithelial tissues  of the grafts, 
as previously reported (7,  10). Even if euthymic recipients 
were administered with anti-Lyt-2 mAb, the allo-MHC class 
I grafts were rejected at the same time as those to untreated 
recipients. In these cases, a large number of CD8 + cells ap- 
peared in the epidermis of the grafts, and some of them were 
infiltrating into the epithelial  tissue, but no CD4 + cells were 
detected in situ (Fig.  2,  a  and b). 
When  the  recipient  of long-surviving  (B6  x  bml)Ft 
grafts was implanted with the same graft or (I36 x  bm12)F1 
skin graft, the first graft was not affected, and no T  cells 
infiltrated into the graft (data not shown). However, when 
(bml  x  bm12)Ft  skin graft was implanted as the second 
graft, the long-standing (B6  x  bml)F1 grafts (four of seven 
cases) were rejected 2-5 d after rejection of the second graft. 
Immunohistochemical examination revealed that in the re- 
jected cases a large number of CD4 + cells were detected at 
the site of the biopsied long-standing allo-dass I graft and 
infiltrated the epidermis and hair tissue (Fig.  2 c). On the 
contrary, few CD8 + cells in the dermis and none in the ep- 
ithelial tissue were detected (Fig. 2 d). In the biopsied samples 
of unrejected cases (three of seven) with long-standing MHC 
class I-disparate grafts, no T  cell infiltration was observed 
(data not shown). The reasons why long-standing dass I-dis- 
parate grafts were not rejected in all cases after implantation 
of the second allo-class I  +  II grafts remain unclear. Clone 
size  of H-2K  bm~ antigen-reactive CD4 + T  cells  might be 
small, and stimulation of such T  cells by allo-class  I  +  II 
grafts might be at a threshold level. 
The previous immunohistochemical results showed that 
CD4 + cells did not infiltrate the epithelial tissues  of allo- 
MHC class I graft, but CD8 + cells did (7, 9,  10). On the 
contrary, the present experiment demonstrated that a large 
number of CD4 + cells were detected in the epithelial tissue 
of the MHC class I-disparate graft in the absence of CD8 + 
cells. These CD4 + cells might be generated by recognizing 
allo-MHC class I antigen in association with sdf-Ia antigen 
(19) and become effectors for the rejection of dass I-bearing 
cells.  In that  process,  CD4 + cells  recognizing allo-MHC 
class  II antigen might  help  the activation of CD4 + cells 
reacting with allo-MHC class I antigen in MHC class I  + 
II-different graft. Thus far, the involvement of CD4 + cells 
in immunological reactions to H-2K  bml antigen has not been 
reported. In previous extensive studies, we could not obtain 
T  cell clones with CD4 + phenotype which responded to 
H-2K  bin1 (20).  A  recent report  by Rosenberg  et  al.  (21) 
showed that MHC class 1-disparate (H-2D) skin graft was 
rejected in CDS-depleted recipients.  They stated that CD8 + 
cells resistant to anti-CD8 mAb mediated the graft rejection. 
However, involvement of CD8 § cells at the site of grafted 
skin was  not examined in  their experiments.  Our report 
directly indicates that  CD4 + cells  are able to become el- 
lectors for the rejection of allo-MHC dass I (H-2K) skin graft 
using immunohistochemical analyses of the graft site. Such 
immune responses might occur under a particular condition 
where CD8 + T cells preferentially responding to MHC dass 
I antigen are absent from the host. Characterization of such 
CD4 + T  cells is a target for further studies. 
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